DDInter1625 DDInter1602
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.
Risankizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Risankizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Risankizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Risankizumab {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Risankizumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Risankizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Risankizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Risankizumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Risankizumab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Risankizumab may lead to a major life threatening interaction when taken with Upadacitinib